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494. Development of a pH Sensor to Probe 
Endosomal Buffering of Polymeric Nanoparticles 
Effective for Gene Delivery
David R. Wilson1, Denis Routkevitch1, Karl J. Wahlin2, Don J. 
Zack2, Alfredo Quinones-Hinojosa3, Jordan J. Green1
1Biomedical Engineering, Johns Hopkins University, Baltimore, 
MD, 2Opthalmology, Johns Hopkins University, Baltimore, MD, 
3Neurosurgery, Johns Hopkins University, Baltimore, MD
Introduction: Polymeric gene delivery suffers from low effi cacy 
compared to viral gene delivery with one of the primary barriers to 
successful transfection being effi cient endosomal escape. Cationic 
polymers have been hypothesized to facilitate endosomal escape 
via the proton sponge mechanism by buffering hydrogen ions in 
the endosomal compartment. Here we have created a nucleic acid 
based pH sensor and applied it using fl ow cytometry and confocal 
microscopy to investigate endosomal buffering of synthetic 
biodegradable cationic polymers for gene delivery, correlating the 
pH of delivered DNA with transfection. Methods: We created a 
nucleic acid pH sensor by conjugating pH sensitive (FITC, OG) and 
insensitive (Cy5) fl uorophores to plasmid DNA. The fl uorescence 
ratio of the sensor was calibrated to pH using fl ow cytometry and 
confocal microscopy following electroporation into cells. Cells were 
transfected with the plasmid pH sensor complexed with cationic 
polymers including poly(beta-amino ester)s (PBAEs) of variable 
transfection effi cacy to investigate endosomal buffering. Additionally, 
confocal microscopy was used to assess colocalization of the plasmid 
pH sensor with a lysosomal dye. Results: PBAEs were demonstrated 
to effectively buffer endosomes and avoid lysosomal fate, whereas the 
negative controls poly-L-lysine (PLL) and polyethylenimine (PEI) 
were shown to accumulate in lysosomes by 24h post-transfection. 
The polymer molecular weight and weight-weight ratio to plasmid 
DNA was shown to have an effect on endosomal buffering as well as 
transfection effi cacy in the case of PBAEs. From confocal microscopy 
analysis of endosomes, local pH was observed to be higher at the 
endosomal membrane than in the center, which may be indicative 
of polymer enrichment along the membrane due to excess soluble 
polymer. Conclusions: The constructed DNA sensor gave a linear 
relationship with intracellular pH. When investigating PBAE-induced 
buffering, results were consistent with the hypothesized proton 
sponge mechanism. These cationic polymers were demonstrated to 
affect endosomal pH and DNA lysosomal fate and lead to successful 
transfection. 
Fig 1: Confocal microscopy was used to assess the compartmental 
pH of endosomes containing nanoparticles formed with the pH sensor. 
Lysosome colocalization is shown in merged thresholded images 
with lysosomes (blue), DNA non-colocalized with lysosomes (pink) 
and DNA colocalized with lysosomes (yellow). Scattergrams show 
DNA fl uorescence (horizontal) and lysosome fl uorescence (vertical). 
Scale bar 10 µm.
Fig 2. Confocal microscopy images were analyzed at (A) 1 hour and 
(B) 24 hours post-transfection using Pearson’s correlation coeffi cient 
M1 to assess the fraction of DNA colocalized with lysosomal stain. 
When delivered via PBAE 447, the fraction of DNA colocalized 
with lysosomes was signifi cantly different than both bPEI and PLL 
at both time points.
495. Activation of DNA Pattern Recognition 
Receptors After Plasmid Electrotransfer in 
Melanoma Cells and Tumors
Loree Heller1, Masa Bosnjak2, Katarina Znidar3, Maja Cemazar2
1Old Dominion University, Norfolk, VA, 2Institute of Oncology 
Ljubljana, Ljubljana, Slovenia, 3University of Primorska, Izola, 
Slovenia
In vivo electroporation or electrotransfer, the application of 
controlled electric pulses, enhances delivery of plasmid DNA to 
a wide variety of healthy tissues as well as many tumor types. 
Electrotransfer of pDNA encoding therapeutic genes substantially 
increases gene expression, enhancing subsequent therapeutic 
effects. Delivery of therapeutic plasmid DNA has reached clinical 
trials in the US and in Europe, primarily for cancer therapies and 
infectious disease vaccines. In several preclinical tumor models, 
delayed tumor growth, increased survival time, and even complete 
tumor regression can occur with intratumoral electroporation, also 
known as electrotransfer, of DNA oligonucleotides or plasmid DNA 
devoid of a therapeutic gene (empty vector). In B16.F10 mouse 
melanomas, these effects are preceded by signifi cant elevation of 
several proinfl ammatory cytokines and chemokines including IFNβ, 
implicating the binding and activation of intracellular DNA-specifi c 
pattern recognition receptors in response to DNA electrotransfer. The 
purpose of this study was to investigate whether melanoma tumors 
and cells express cytosolic DNA sensors and whether these sensors 
respond to pDNA electrotransfer. Histologically, tumor necrosis 
independent of caspase-3 was observed. Although the mRNAs for 
several DNA sensors were detected in tumors, none was signifi cantly 
upregulated. In B16.F10 cells in culture, IFNβ mRNA and protein 
levels were signifi cantly upregulated after pDNA electrotransfer. 
The mRNAs for several DNA sensors were present in these cells 
and DAI, DDX60, and p204 mRNAs were signifi cantly upregulated 
after pDNA electrotransfer. DDX60 protein levels were coordinately 
upregulated. Mirroring the observation of tumor necrosis, cells 
underwent a signifi cant pDNA concentration-dependent decrease in 
proliferation and survival. Taken together, increased IFNβ and DNA 
sensor expression accompanied by cell death and tumor necrosis 
indicate that pDNA electrotransfer activates intracellular DNA 
sensors in B16.F10 cells and tumors, producing both in vitro and in 
vivo effects. The absence of activation of DNA sensors in vivo could 
be due to the lower transfection effi ciency compared to that in vitro 
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or to dilution by other tumor cell types. Electrotransfer is an effi cient 
means of enhancing plasmid DNA introduction into tissues such 
as skin, muscle, and tumors for therapeutic application. Localized 
infl ammation and induced cell death may contribute to cancer gene 
therapies but may impede gene therapies for which these effects are 
not desirable.
496. Elucidating Design Rules Governing 
Extracellular Vesicle-Mediated Therapeutic Protein 
Delivery
Michelle E. Hung, Joshua N. Leonard
Chemical and Biological Engineering, Northwestern University, 
Evanston, IL
Extracellular vesicles (EVs) are secreted biological nanoparticles 
that have great potential as therapeutic delivery vehicles - they are 
well-tolerated in vivo and naturally capable of transferring RNA and 
proteins between cells. Our ability to engineer EVs as therapeutic 
delivery vehicles is limited by an incomplete understanding of how 
EVs load biomolecular cargo and deliver it to recipient cells. In 
particular, the biophysical rules governing mRNA and protein delivery 
by EVs have not been elucidated. Open questions include: Does size 
limit mRNA loading effi ciency into EVs? To what extent is EV mRNA 
cargo translated in recipient cells? What factors impact the degree 
to which RNA and protein cargo are delivered to the cytoplasm of 
recipient cells?
To quantitatively investigate the above questions, we leveraged 
our Targeted and Modular EV Loading (TAMEL) platform, which 
enables active loading of specifi c cargo RNA into EVs. TAMEL can 
enrich cargo mRNA loading into EVs up to 40-fold relative to passive 
loading. By directly comparing active loading effi ciencies between 
mRNAs of different lengths, we characterized what type of RNAs 
can be loaded into EVs. While active loading of mRNA-length (> 
1.5 kb) cargo molecules was signifi cant, active loading was much 
more effi cient for smaller (~0.5 kb) RNA molecules, providing the 
fi rst direct evidence for the impact of cargo RNA size on loading 
into EVs. We next leveraged the TAMEL platform to elucidate the 
limiting steps in EV-mediated delivery of mRNA and protein to 
prostate cancer cells, as a therapeutically relevant model system. In 
this model system, we did not observe translation of EV-delivered 
mRNA in recipient cells, indicating this is a limiting step in functional 
delivery of EV cargo. In contrast, we observed robust EV-mediated 
delivery of dTomato reporter protein, and thus further explored EVs 
as therapeutic protein delivery vehicles.
To probe the effi cacy of EV-mediated therapeutic protein delivery, 
we investigated using EVs to deliver the prodrug converting enzyme 
cytosine deaminase fused to uracil phosphoribosyl transferase 
(CD-UPRT), which converts the prodrug 5-FC to the toxic 5-FU. 
Importantly, CD-UPRT can function without without requiring 
endosomal escape because both 5-FC and 5-FU are membrane 
permeable. We also explored strategies for EV-mediated delivery of 
Cas9 nuclease, which must overcome the EV loading barrier imposed 
by its NLS sequence as well as escape the endosome in recipient 
cells. To address the loading challenge, we investigated a strategy 
for conditional NLS reconstitution to allow enhanced loading of 
Cas9 into EVs. We then used Cas9 delivery to assess the degree to 
which EV-delivered proteins can escape the endosomal/lysosomal 
pathways and traffi c to other subcellular locations. Altogether, our 
investigations elucidated key design rules and central limiting steps 
that may guide the further development and utilization of EVs as 
therapeutic biomolecule delivery vehicles.
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497. Follistatin Gene Therapy Improves Six 
Minute	Walk	Distance	in	Sporadic	Inclusion	Body	
Myositis (sIBM)
Jerry R. Mendell, Zarife Sahenk, Mark Hogan, Samiah Al-Zaidy, 
Kevin Flanigan, Louise R. Rodino-Klapac, Markus McColly, 
Kathleen Church, Sarah Lewis, Linda Lowes, Lindsay Alfano, 
Katherine Berry, Natalie Miller, Igor Dvorchik, Melissa Moore-
Clingenpeel, Brian K. Kaspar
Gene Therapy, The Research Institute at Nationwide Children’s 
Hospital, Columbus, OH
Treatment of sIBM poses many challenges. The cause of 
this disease is enigmatic, and although considered to be an 
infl ammatory myopathy, there is resistance to anti-infl ammatory and 
immunosuppressive agents. sIBM muscle biopsies show vacuolated 
muscle fi bers, widespread infl ammation, and intracellular amyloid 
deposits. Follistatin is a potent inhibitor of the myostatin pathway 
and its potential as a therapeutic vehicle is enhanced by a pathway 
independent of the activin IIB receptor. We have demonstrated 
both safety and effi cacy following direct intramuscular injection of 
follistatin in the quadriceps muscle in a previously reported gene 
therapy trial in Becker muscular dystrophy (Mendell JR, et al Mol 
Ther 2015). No off target effects were encountered attributed to the 
use of an alternatively spliced follistatin isoform, FS344, also used 
in the current sIBM gene therapy trial. Enrollment in the current 
gene therapy trial included 6 subjects with either defi nite or possible 
sIBM (Griggs RC, et al. Ann Neurol 1995). Pretreatment MRI’s were 
obtained to determine areas of relative muscle sparing/lack of fi brosis. 
The intramuscular injections of AAV1.CMV.FS344 to 12 to 14 sites 
in the quadriceps muscle delivered 1.2X1012 vg/kg. Injections were 
performed with direct ultrasound guidance to target the most normal 
appearing muscle bundles, and intramuscular position was confi rmed 
with simultaneous EMG. A three-patient, single limb, safety trial 
preceded the Phase I/IIA trial reported here. During the ongoing gene 
therapy trial, a control sIBM group (n=20) was prospectively studied 
by performance of the 6MWT with follow up from 9-28 months.
The 6MWT was the primary functional outcome (See table below). 
sIBM patients treated with AAV1.CMV.FS344 increased the 6MWT 
distance by 46.5m (457 to 503.5, p =0.001). Untreated sIBM controls 
lost 38.5m over a similar time period resulting in net difference of 
85.0m between groups (p=0.0007). To validate fi ndings and confi rm 
the lack of selection bias we compared a subgroup of untreated sIBM 
controls (n=8), matched for age, gender, and 6MWD at baseline. 
Matched controls lost 39m (p=0.0036) in the 6MWD, a virtually 
identical loss to the larger control group.
The results of this study demonstrate that sIBM can benefi t from 
follistatin gene therapy based on improvement in distance walked 
in the 6MWT. We did fi nd a hierarchy of response based on muscle 
preservation and avoiding gene delivery to areas of fi brosis. In this 
study, gene delivery was limited to the quadriceps muscle, but in 
future trials more widespread delivery could potentially be more 
effective.
Six Minute Walk Distance Pre- and Post-Treatment• (median values (interquartile ranges provided)] 
Group Baseline(m) Final Compared to Change from Change per Baseline(m) Baseline (m) Month (m) 
slBM Gene Therapy Pts 457 Improved to 503.5 +46.5 
+3.09 (0.39,8.9) (n =6) (431,475) (443,573) (2,117) 
Untreated sIBM Controls 393 Declined to 354.5 -38.5 (-73,-22) -2.3 (-4,-1.1) 
(n=20) (356.5,.45 1.5) (303.5,410.5) p :0.0007 P=0.0032 
Matched slBM Controls 459 Declined to 420 -39.0(-77, -8) -2.2 (-4.8,-0.7) forage,gender, (439.5,469) (388.5,447.5) p = 0.0036 P=0.0118 
and 6MWD (n = 8) 
